News Image

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

Provided By GlobeNewswire

Last update: Jun 23, 2025

16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients

Robust central nervous system (CNS) activity; 41% (7/17) confirmed complete response (CR) and 53% confirmed overall response (ORR) in CNS evaluable disease patients by BICR in overall cohort

Read more at globenewswire.com

ARRIVENT BIOPHARMA INC

NASDAQ:AVBP (7/24/2025, 8:23:10 PM)

After market: 21.45 0 (0%)

21.45

-0.44 (-2.01%)



Find more stocks in the Stock Screener

Follow ChartMill for more